Related Experiment Video
Updated: Jul 3, 2025
08:18
Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
3.3K
Naringenin Nanoformulations for Neurodegenerative Diseases
Liza Sahoo1, Nigam Sekhar Tripathy1, Fahima Dilnawaz1
1Department of Biotechnology, School of Engineering and Technology, Centurion University of Technology and Management, Jatni, 752050, Bhubaneswar, Odisha, India.
Current Pharmaceutical Biotechnology
|February 13, 2024
Summary
Naringenin nanoformulations show promise for treating brain tumors like glioblastoma. These delivery systems can overcome drug resistance and improve outcomes for neurological diseases.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Pharmacology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Drug resistance and invasion limit current GBM treatments.
- Naringenin (NRG) is a flavanone with potential CNS therapeutic applications.
Purpose of the Study:
- To review naringenin-loaded nanoformulations for brain tumor treatment.
- To explore nanocarrier systems for enhancing naringenin delivery.
- To assess the therapeutic potential of NRG nanoformulations in neurological diseases.
Main Methods:
- Review of existing literature on naringenin nanoformulations.
- Discussion of various nanocarrier types (nanoparticles, liposomes, etc.).
- Analysis of in vitro and in vivo studies using NRG nanoformulations.
Main Results:
- Naringenin can cross the blood-brain barrier when formulated in nanocarriers.
- Various nanoformulations demonstrate efficacy in preclinical models.
- NRG-loaded systems offer a strategy to overcome GBM drug resistance.
Conclusions:
- Naringenin-loaded nanoformulations represent a promising therapeutic strategy for glioblastoma.
- These systems hold potential for treating various neurological disorders.
- Further research into NRG nanoformulations could advance brain cancer therapy.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
01:26Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K